Search Result

Isoforms Recommended:	Phospholipase A

Results for "

Lp-PLA2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Phospholipase (21)
By Research Areas:	Cancer (1) Cardiovascular Disease (6) Inflammation/Immunology (4) Metabolic Disease (8) Neurological Disease (15)

Inhibitors & Agonists

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-133149

Lp-PLA2-IN-3	Phospholipase	Cardiovascular Disease
Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC₅₀ of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2) .

HY-133148

Lp-PLA2-IN-2	Phospholipase	Inflammation/Immunology
Lp-PLA2-IN-2 is a potent and selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC₅₀ 0f 120 nM for recombinant human Lp-PLA2 .

HY-142774

Lp-PLA2-IN-6	Phospholipase	Neurological Disease
Lp-PLA2-IN-6 (compound 18), a tetracyclic pyrimidinone compound, is a potent *Lp-PLA2* inhibitor with a pIC₅₀ of 10.0 for rhLp-PLA2. Lp-PLA2-IN-6 has the potential for neurodegenerative related diseases research .

HY-142777

Lp-PLA2-IN-9	Phospholipase	Neurological Disease
Lp-PLA2-IN-9 (compound 17), a tetracyclic pyrimidinone compound, is a potent *Lp-PLA2* inhibitor with a pIC₅₀ of 10.1 for rhLp-PLA2. Lp-PLA2-IN-9 has the potential for neurodegenerative related diseases research .

HY-160637

Lp-PLA2-IN-17	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lp-PLA2-IN-17 (Compound 39) is an inhibitor of *Lp-PLA₂. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA₂* .

HY-142669

Lp-PLA2-IN-4	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .

HY-142670

Lp-PLA2-IN-5	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .

HY-142779

Lp-PLA2-IN-11	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .

HY-153559

Lp-PLA2-IN-13	Phospholipase	Neurological Disease
Lp-PLA2-IN-13 (compound 15) is a potent *Lp-PLA2* inhibitor. Lp-PLA2-IN-13 has the potential for the research of neurodegenerative related diseases .

HY-19757

Lp-PLA2-IN-1	Phospholipase	Cardiovascular Disease Neurological Disease
Lp-PLA2-IN-1 is a potent Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2-IN-1 has the potential for atherosclerosis, Alzheimer's disease research .

HY-153183

Lp-PLA2-IN-12	Phospholipase	Cardiovascular Disease Neurological Disease
Lp-PLA2-IN-12 (compound 19) is an *Lp-PLA2* inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis .

HY-142778

Lp-PLA2-IN-10	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .

HY-153560

Lp-PLA2-IN-14	Phospholipase	Neurological Disease
Lp-PLA2-IN-14 (Compound 19) is an *Lp-PLA2* inhibitor with a pIC₅₀ of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .

HY-153561A

Lp-PLA2-IN-16	Phospholipase	Neurological Disease
Lp-PLA2-IN-16 (example 1) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .

HY-153561

Lp-PLA2-IN-15	Phospholipase	Neurological Disease
Lp-PLA2-IN-15 (example 2) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .

HY-145653

GSK2647544	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
GSK2647544 is an orally available, selective inhibitor of *Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2*) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived macrophages .

HY-19415

SB-435495

Phospholipase Metabolic Disease

SB-435495 is a potent, selective, reversible, non-covalent and orally active Lp-PLA₂ inhibitor with an IC₅₀ of 0.06 nM .

SB-435495	Phospholipase	Metabolic Disease
SB-435495 is a potent, selective, reversible, non-covalent and orally active *Lp-PLA₂* inhibitor with an IC₅₀ of 0.06 nM .

HY-19415A

SB-435495 hydrochloride	Phospholipase	Metabolic Disease
SB-435495 hydrochloride is a potent, selective, reversible, non-covalent and orally active *Lp-PLA₂* inhibitor with an IC₅₀ of 0.06 nM .

HY-19415B

SB-435495 ditartrate	Phospholipase	Metabolic Disease
SB-435495 ditartrate is a potent, selective, reversible, non-covalent and orally active *Lp-PLA₂* inhibitor with an IC₅₀ of 0.06 nM .

HY-102004

Rilapladib 1 Publications Verification SB 659032	Phospholipase	Neurological Disease Inflammation/Immunology
Rilapladib (SB 659032) is a selective *Lp-PLA₂* (lipoprotein-associated phospholipase A₂) inhibitor with an IC₅₀ of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist ^[2].

HY-10521

Darapladib 5 Publications Verification SB-480848	Phospholipase Apoptosis	Cardiovascular Disease Cancer
Darapladib (SB-480848) is an orally active, selective and reversible *Lp-PLA2* inhibitor (IC₅₀=0.25 nM). Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer ^[2] .

Species:	Mouse (2)
Tag:	His (2) Myc (2)
Source:	HEK293 (1) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P700568

	PLA2G7 Protein, Mouse (HEK293, N-His, C-Myc) PLA2G7; phospholipase A2, group VII (PLAtelet-activating factor acetylhydrolase, PLAsma); PLAtelet-activating factor acetylhydrolase; LDL PLA2; PAFAH; LDL-PLA(2); gVIIA-PLA2; PAF 2-acylhydrolase; PAF acetylhydrolase; group-VIIA phospholipase A2; LDL-associated phospholipase A2; lipoprotein-associated phospholipase A2; 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycerophosphocholine esterase; PAFAD; Lp-PLA2; LDL-PLA2	Mouse	HEK293
	The PLA2G7 protein is a lipoprotein-associated calcium-independent phospholipase A2 that plays a key role in phospholipid catabolism during inflammation and oxidative stress responses. It acts at the lipid-water interface and hydrolyzes the ester bond of the fatty acyl group at the sn-2 position, with particular preference for short-chain fatty acyl groups. PLA2G7 Protein, Mouse (HEK293, N-His, C-Myc) is the recombinant mouse-derived PLA2G7 protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of PLA2G7 Protein, Mouse (HEK293, N-His, C-Myc) is 419 a.a., with molecular weight of 51.9 kDa.

HY-P700567

	PLA2G7 Protein, Mouse (Baculovirus, N-His, C-Myc) PLA2G7; phospholipase A2, group VII (PLAtelet-activating factor acetylhydrolase, PLAsma); PLAtelet-activating factor acetylhydrolase; LDL PLA2; PAFAH; LDL-PLA(2); gVIIA-PLA2; PAF 2-acylhydrolase; PAF acetylhydrolase; group-VIIA phospholipase A2; LDL-associated phospholipase A2; lipoprotein-associated phospholipase A2; 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycerophosphocholine esterase; PAFAD; Lp-PLA2; LDL-PLA2	Mouse	Sf9 insect cells
	The PLA2G7 protein is a lipoprotein-associated calcium-independent phospholipase A2 that plays a key role in phospholipid catabolism during inflammation and oxidative stress responses. It acts at the lipid-water interface and hydrolyzes the ester bond of the fatty acyl group at the sn-2 position, with particular preference for short-chain fatty acyl groups. PLA2G7 Protein, Mouse (Baculovirus, N-His, C-Myc) is the recombinant mouse-derived PLA2G7 protein, expressed by Sf9 insect cells , with C-Myc, N-10*His labeled tag. The total length of PLA2G7 Protein, Mouse (Baculovirus, N-His, C-Myc) is 419 a.a., with molecular weight of 50.7 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.